RLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Relmada Therapeutics Inc (RLMD) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong insider buying trends, positive analyst sentiment with increasing price targets, and a promising drug pipeline. Despite weak financial performance, the long-term potential of its NDV-01 treatment and bullish technical indicators make it a favorable choice.
The stock's technical indicators are mixed but lean bullish. The MACD histogram is below zero and negatively contracting, indicating a weak bearish trend. However, the RSI is neutral at 54.547, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 7.328, with key support at 6.896 and resistance at 7.76.
Analysts have issued positive ratings with increasing price targets, citing the potential of NDV-01 as a best-in-class treatment.
Insider buying has surged by 1133.44% over the last month, indicating confidence from company insiders.
The stock has a 60% chance of gaining 4.91% in the next week based on historical patterns.
Financial performance remains weak, with negative net income and declining EPS (-46.77% YoY).
High implied volatility (103.
and low IV percentile (6.
suggest uncertainty and limited options activity.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$19.87 million, which improved by 6.49% YoY. EPS dropped significantly by -46.77% YoY to -0.33. Gross margin remained at 0%.
Analysts are optimistic about RLMD. Piper Sandler initiated coverage with an Overweight rating and a $12 price target, citing the advantages of NDV-01. Mizuho raised its price target to $19 from $10, highlighting better-than-expected durability data and strong execution. Lucid Capital initiated coverage with a Buy rating and a $14 price target, emphasizing NDV-01's differentiation in treatment.
